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Background: Type 2 myocardial infarction (MI) is characterized by an imbalance between myocardial 
blood supply and demand, leading to myocardial ischemia without coronary plaque rupture, but its 
diagnosis is challenging.  
Methods: In the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary 
Syndrome (TRACER) trial, patients with non-ST-segment elevation acute coronary syndromes were 
included. We aimed to describe provoking factors, cardiac biomarker profiles, treatment patterns, and 
clinical outcomes of patients with type 2 MIs. MI events during trial follow-up were adjudicated by an 
independent clinical events classification committee (CEC) and were classified according to the Third 
Universal Definition of MI. Using available source documents retrieved as part of the CEC process, we 
performed a retrospective chart abstraction to collect details on the type 2 MIs. Cox regression models 
were used to explore the association between MI type (type 1 or type 2) and all-cause death. 
Results: Overall, 10.3% (n=1327) of TRACER participants had a total of 1579 adjudicated MIs during a 
median follow-up of 502 days (interquartile range [IQR] 349–667). Of all MIs, 5.2% (n=82) were CEC-
adjudicated type 2 MIs, occurring in 76 patients. The incidence of type 2 MI was higher in the first month 
following randomization, after which the distribution became more scattered. The most frequent potential 
provoking factors for type 2 MIs were tachyarrhythmias (38.2%), anemia/bleeding (21.1%), 
hypotension/shock (14.5%), and hypertensive emergencies (11.8%). Overall, 36.3% had a troponin 
increase >10× the upper limit of normal. Coronary angiography was performed in 22.4% (n=17) of 
patients during hospitalizations due to type 2 MIs. The hazard of death was numerically higher following 
type 2 MI (vs. no MI, adj. HR 8.25, 95% CI 4.57–14.92; p<.0001) than that of type 1 MI (vs. no MI, adj. 
HR 5.71, 95% CI 4.62–7.06; p<.0001). 
Conclusions: Type 2 MIs were more prevalent in the first month after ACS were characterized by the 
presence of triggers and infrequent use of an invasive strategy, and were associated with a high risk of 
death. Further efforts are needed to better define the role and implications of type 2 MI in both clinical 





































Type 2 myocardial infarction (MI) is defined as myocardial necrosis caused by an imbalance between 
myocardial blood supply and demand, without coronary plaque rupture
 
(1). In clinical practice, type 2 MI 
is typically identified in the context of predisposing conditions, such as tachyarrhythmia, hypotension, 
sepsis, decompensate heart failure, and acute anemia, among others. While in some cases the supply-
demand mismatch mechanism is clear, in other situations the diagnosis of type 2 MI is often based on 
subjective interpretation of the clinical context. This leads to difficulties in decision-making for these 
patients, especially regarding the use of antithrombotic medications and use of invasive strategies.  
Uncertainties in the attribution of the correct type of MI are also reflected by the wide variation in 
the reported relative occurrence of type 2 MI (3–26% of all MIs) in several studies (2-8). Moreover, the 
availability of high-sensitivity troponin assays will likely increase the number of patients who have 
elevated biomarkers in a variety of clinical conditions (9). Finally, the prognostic significance of type 2 
MI is not well defined. 
Further description of type 2 MI characteristics may benefit both clinical practice and randomized 
trials. In the clinical research setting, clearer definitions may help to identify MI outcomes that are likely 
to be influenced by study treatment. Using the framework of the Thrombin Receptor Antagonist for 
Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial, we sought to describe clinical 
characteristics and prognoses associated with MI identified as type 2 by a central adjudication committee.  
 
METHODS 
Patients and Study Design 
The design and main results of the TRACER trial have been published (10). In summary, it was a 
randomized, multinational, double-blinded clinical trial that included high-risk patients with non-ST-
segment elevation acute coronary syndromes (ACS). To be included, participants had to present with 
symptoms of ischemia within 24 hours prior to hospitalization in addition to troponin or CK-MB 

















diabetes, peripheral arterial disease, previous MI, percutaneous coronary intervention (PCI) or coronary 
artery bypass graft (CABG). Key exclusion criteria were: use of anticoagulants or inducers/inhibitors of 
CYP3A4 isoenzymes, history of bleeding diathesis, any previous intracranial bleeding, and severe valve 
heart disease. Participants were randomized in a 1:1 ratio to receive a loading dose of vorapaxar (40 mg at 
least 1 hour before any revascularization procedure), followed by 2.5 mg daily, or placebo, on top of 
standard antiplatelet therapy. The study treatment was to be given for at least 1 year. All patients provided 
informed consent to participate in the TRACER trial. The authors are solely responsible for the design 
and conduct of this study, all study analysis, the drafting and editing of the paper, and its final contents. 
The TRACER trial was supported by Merck & Co., Inc. 
 
 
Type 2 MI Event Data Collection 
MI events were prospectively adjudicated by an independent clinical events classification committee 
(CEC) blinded to treatment assignment, and were classified in MI types according to the Third Universal 
Definition of MI (1). The definitions of MI used in the TRACER trial have been previously published 
(11). Type 2 MIs were defined as events likely caused by supply/demand mismatch and in which the 
mechanism of ischemia was thought to be something other than acute coronary plaque flow-limiting 
events. Using available source documents retrieved as part of the CEC adjudication process, we 
performed a retrospective chart abstraction (abstractor P.O.G.) to collect additional details on clinical 
scenarios surrounding the MI presentation and the management of CEC-defined type 2 MIs. We searched 
the event case report form to identify event characteristics such as the presence and type of symptoms, 
biomarker values with respective local lab normal range values, coronary angiogram and PCI reports, and 
additional information in the narrative that highlighted the predisposing condition that led the adjudicator 
to classify the MI as type 2. This assessment was blinded to treatment assignment and clinical outcomes. 

















the main trial database such as biomarker patterns, concomitant treatments, use of coronary angiogram 
and revascularization procedures, and clinical outcomes.  
 
Statistical Analysis 
Baseline characteristics are presented for patients with no MI during trial follow-up, type 1 MI, and type 2 




 percentiles, and categorical 
variables are presented as counts with associated percentages. 
Cox proportional hazards models were used to examine the association between first MI type 
(type 1 or type 2) versus no MI and all-cause death. Occurrences of MIs post-randomization were treated 
as a time-varying covariate. The model was adjusted for important baseline factors, including 
demographic characteristics (age, sex, race, weight, region), medical history (smoking, hypertension, 
diabetes, hyperlipidemia, prior peripheral arterial disease, MI, stroke, PCI, CABG), features on 
presentation (ST-segment deviation, new T wave, Killip class, renal insufficiency), and treatments 
received during index stay (cardiac catheterization, PCI, CABG, clopidogrel, aspirin, glycoprotein IIb/IIIa 
inhibitors, study treatment). We performed two sensitivity analyses: a) one considering the last MI before 
the death event, and b) one excluding patients with multiple MI events. Results are presented as hazard 
ratios (HRs) with 95% confidence intervals (CIs). Analyses were performed using SAS software, version 
9.3 (SAS Institute, Inc., Cary, NC). All tests were 2-sided, and a p-value <0.05 was considered 
statistically significant. No adjustment was made for multiple comparisons. All analyses were performed 




Overall, 1327 TRACER participants experienced a total of 1579 CEC-confirmed MIs during a median 
follow-up of 502 days (interquartile range [IQR] 349–667). A total of 82 MIs (5.2% of all MIs) were 

















type 1 and type 2 MIs during trial follow-up. The timing of first type 1 MI and type 2 MI since 
randomization is shown in Figure 1. We observed that the occurrence of type 1 MI was more frequent in 
the first months after randomization and decreased and became more homogenous throughout follow-up. 
For type 2 MI, the incidence was higher in the first month, after which the distribution became more 
scattered. The distributions of type 2 MIs were not different among those who received PCI at index 
hospitalization vs. those who did not. Among the 57 subjects who had type 2 MI after 30 days of 
randomization, 84.2% had MI as the index event. Among those who had type 2 MIs within 30 days of 
randomization (n=19), 36.8% underwent PCI at index hospitalization. 
Baseline characteristics of patients with any type 1 MI, any type 2 MI, and no MIs are presented 
in Table 1. Among patients with type 2 MIs, the median age was 71 years, and 30.3% were female. 
Patients with type 2 MIs were older, more likely to be smokers, have hyperlipidemia, and have a history 
of prior MI or CABG than those with no MIs. Additionally, creatinine clearance <30 mL/min was more 
frequent among patients with type 2 MIs, in comparison with those with no MIs, and hemoglobin levels at 
baseline were lower among those with type 2 MIs. Hypertension and diabetes were more common among 
patients with type 1 MIs, in comparison with those with no MIs. More patients with type 1 or type 2 MIs 
had ≥4 comorbidities in comparison with those with no MIs. During index hospitalization, coronary 
angiography, PCI, and the use of glycoprotein IIb/IIIa inhibitors were less common among patients with 
type 2 MIs, compared with those with type 1 MIs or no MIs.  
 
Type 2 MI Event Characteristics and Management 
Of all patients experiencing type 2 MIs, 65.8% (n=50) had chest pain or typical angina-like symptoms, 
11.8% (n=9) had atypical chest discomfort, and 21.1% (n=16) did not have symptoms clearly attributable 
to ischemia. The most common associated condition considered to be provocative of the supply/demand 
mismatch were tachyarrhythmia, anemia or bleeding, hypotension or shock, sepsis or infection, 

















potential causal condition was present. Of all patients with type 2 MI due to anemia/bleeding, 84.6% 
(n=16) had GUSTO moderate/severe bleeding from a gastrointestinal source.  
One-third of patients with type 2 MI had troponin peak between 1–3× the upper limit of normal 





percentiles) ratio of peak troponin and ULN was 10.7 (3.2, 40.8) for type 1 MI and 4.3 (1.9, 26.5) for type 
2 MI. 
During the acute treatment of type 2 MI, 72.4% of patients received aspirin, 51.3% received 
clopidogrel, and 13.7% received heparin. Coronary angiography during the hospitalization for type 2 MI 
was performed in 22.4% (n=17) of patients. Among those who received angiography, 9 had coronary 
stenosis ≥70%, and 3 of them underwent PCI. 
 
All-cause Death Following MI Events 
Estimated cumulative cardiovascular death rates following type 1 MI and type 2 MI are shown in Figure 
2. Type 2 MI was associated with a 12-fold increase in the hazard of cardiovascular death (HR 11.82, 
95% CI 5.71–24.46; p<.001) compared with no MI (Table 3). For patients with type 1 MI, the HR for 
cardiovascular death was 8.90 (95% CI 6.93–11.43; p<.0001) compared with no MI. In the analysis 
accounting only for the last MI prior to the cardiovascular death event, type 2 MI was associated with a 
19-fold increase in the hazard of death (HR 19.15, 95% CI 10.22–35.88; p<.0001), compared with no MI. 
When patients with multiple MIs were excluded, the HR for cardiovascular death following type 2 MI 
was 14.62 (95% CI 7.04–30.34; p<.0001).  
When considering the hazard of all-cause death, the HR following type 2 MI was 8.25 (95% CI 
4.57–14.92; p<.001) vs. no MI. The HR for all-cause death following type 1 MI was 5.71 (95% CI 4.62–
7.06; p<.0001) vs. no MI. When accounting only for the last MI prior to the death event, type 2 MI was 
associated with a 12-fold increase in the hazard of all-cause death (HR 12.54, 95% CI 7.47–21.06; 
p<.0001) compared with no MI. In the analysis excluding patients with multiple MIs, the HR for all-cause 

















 Of the deaths following type 2 MI (n=19), the majority were cardiovascular (68.4%), 21.1% were 
non-cardiovascular, and 10.5% had unknown causes. Among deaths following type 1 MI (n=156), 75.0% 
were cardiovascular, 22.4% were non-cardiovascular, and 2.6% had unknown causes.  
 
DISCUSSION 
In a large clinical trial database of non-ST-segment elevation ACS patients with central adjudication of 
events and independent classification of MI type, we described presentation, treatments, and prognosis of 
type 2 MI. Our key findings are the following. First, type 2 MI was a relatively infrequent event, 
comprising only about 5% of all MIs. The incidence of type 2 MI was higher in the first month following 
randomization, after which the distribution became more scattered. Second, a variety of different triggers 
were thought to have provoked supply and demand mismatch, with tachyarrhythmias and anemia or 
bleeding among the most common mechanisms. Third, contrary to the common perception that type 2 
MIs are characterized by small biomarker leaks, we observed that one-third of patients had major troponin 
elevation. Fourth, type 2 MI tended to be managed conservatively; yet about one-quarter of patients 
received a coronary angiography during type 2 MI hospitalization, with only 3 patients having undergone 
PCI. Finally, type 2 MIs were associated with a high risk of death, and the majority of deaths following 
type 2 MIs were from cardiovascular causes.  
The prevalence of type 2 MI is between 3% and 26% in observational cohorts (3, 5, 12-14) and in 
clinical trials (15, 16). In our study, about 5% of MIs were deemed to be type 2 by the CEC. The 
assessment of type 2 MI is mostly based on subjective interpretation in determining the most likely 
trigger of ischemia. While in some scenarios the identification of a predisposing condition may be clear 
(i.e., bleeding followed by MI), in others it may be quite difficult to determine whether the MI was a 
cause or a consequence, such as in patients with tachyarrythmias or heart failure (17). Moreover, 
differentiating between type 2 MI (i.e., ischemia) and acute myocardial injury (i.e., toxin or other 
mechanisms) in settings of sepsis or following non-cardiac surgeries can be controversial (18-20). 

















category, reserving the term “MI” for coronary occlusion-related events (21, 22). This strategy could 
potentially reduce the heterogeneity of these definitions among clinicians and researchers, but at the same 
time may lead to excessive simplification and grouping of events that are different in nature.  
The presence of symptoms of ischemia may be clinically helpful to distinguish ischemia-driven 
events from those caused by other mechanisms, although identification of symptoms may be challenging, 
especially in critically ill patients. In our study, we observed that more than half of the patients with type 
2 MIs presented with chest pain and symptoms thought to be typical of ischemia, which is in accordance 
with previous studies (2, 4, 5). It has been previously observed that atypical presentation is much more 
common among type 2 MIs than type 1 MIs (23). With the availability of high-sensitivity troponin essays, 
the incidence of myocardial necrosis due to supply and demand mismatch is likely to increase (9). 
Because MI is an almost ubiquitous outcome used in clinical trials, the absence of clear characterization 
of type 2 MI may potentially jeopardize the evaluation of treatment effect of cardiovascular therapies.  
In our study, 22.4% of patients with type 2 MI underwent coronary angiography during hospital 
admission and few of them underwent PCI. Others have shown a lower frequency of invasive procedures 
in patients with type 2 MIs, compared with those with type 1 MIs (2, 3, 5). However, these findings may 
be affected by the assessment criteria used (i.e., an MI that was not treated invasively may be more likely 
to be assigned to the type 2 category). The prognostic benefit of revascularization in the setting of 
secondary ischemia has not been investigated, and invasive procedures may be contraindicated in certain 
conditions. We have also observed lower rates of antithrombotic therapy among patients experiencing 
type 2 MIs, which may be in part explained by the fact that a substantial number of them had acute 
anemia or bleeding. Because of the high risk of cardiovascular events following type 2 MI, the benefit of 
more aggressive management, when not contraindicated, may need further assessment. 
The prognosis of type 2 MI is not well established. Patients experiencing a type 2 MI in the 
TRITON-TIMI 38 trial were at a 3-fold increased risk of cardiovascular death over the following 180 
days, in comparison with those with no recurrent MIs (15). We have observed an increased hazard of 

















those with no MIs— which was at least as high as observed following type 1 MIs. A recent study with 
1251 patients undergoing coronary or peripheral arterial angiography showed that patients with type 2 MI 
had an increased risk of all-cause mortality (HR 2.96, 95% CI 2.01–4.36; p<.001) in comparison with 
those without type 2 MIs (24). Additionally, observational studies have shown similar or higher mortality 
rates among patients with type 2 compared with type 1 MIs (4, 5, 25). Interestingly, although the increase 
in mortality with type 2 MI could be due to co-existing morbidity, we observed that the majority of deaths 
were from cardiovascular causes. Further efforts are needed to clarify the mechanism of disease 
progression in patients with type 2 MI.  
 Our study has several limitations. While the TRACER trial was large in size, the cohort of 
patients with type 2 MI is small, limiting the amount of information included. Many data used were not 
prospectively collected but retrieved by retrospective chart abstraction using clinical source documents 
obtained for the purpose of event adjudication. Some information was missing for some patients. Data on 
non-invasive coronary and myocardial imaging, which could have been helpful to understand ischemic 
burden in patients with type 2 MI, were not collected in the trial. Additionally, we are unable to confirm 
the reasons prompting measurement of cardiac biomarkers in patients without primarily ischemic 
symptoms. Finally, the TRACER trial included non-ST-segment elevation ACS as a criterion for 
eligibility; thus, our population was pre-selected and our results might not be applicable to patients 
without known coronary artery disease. It is important to note that 88% of the overall TRACER 
population underwent coronary angiography and 58% underwent PCI during index hospitalization; 
therefore, most of these patients had significant coronary lesions and were on secondary prevention with 
dual antiplatelet therapy.  
 
CONCLUSIONS 
Type 2 MIs were more prevalent in the first month after ACS, were characterized by the presence of 
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Figure 1. Timing of type 1 MI and type 2 MI since randomization 
Abbreviations: MI, myocardial infarction. 
 
Figure 2. Estimated cumulative cardiovascular death rates following type 1 MI and type 2 MI 


















Table 1. Baseline characteristics and index hospitalization treatments of patients with no MI, type 1 
MI, or type 2 MI 
  No MI 
(N=11,617) 
Type 1 MI 
(N=847) 
Type 2 MI 
(N=76) 





 64 (58-71) 66 (59-74) 71 (62-79) 
Female sex
†
 3244 (27.9) 263 (31.1) 23 (30.3) 
Body weight, kg 80.0 (70.0-92.0) 80.0 (69.9-94.0) 80.0 (70.0-93.7) 
Hypertension
†
 8101 (69.8) 688 (81.2) 60 (78.9) 
Hyperlipidemia
†‡
 7128 (61.4) 625 (73.8) 58 (76.3) 
Diabetes
†
 3510 (30.2) 419 (49.5) 27 (35.5) 
Smoking
†‡
 3731 (32.1) 304 (35.9) 36 (47.4) 
Prior MI
†‡
 3221 (27.7) 416 (49.1) 37 (48.7) 
Prior CABG
†‡
 1244 (10.7) 223 (26.3) 26 (34.2) 
Number of comorbidities
†‡
    
0–3 10451 (90.1) 606 (71.5) 53 (69.7) 
4–6 1128 (9.7) 232 (27.4) 23 (30.3) 





 14.1 (13.0-15.1) 13.5 (12.1-14.8) 13.0 (11.2-14.7) 
CrCl <30 mL/min
†‡
 142 (1.3) 38 (4.7) 7 (9.2) 
Thienopyridine at baseline 10,116 (87.1) 744 (87.8) 67 (88.2) 
Killip class
†‡
    
I 11012 (95.7) 749 (88.7) 65 (85.5) 
II 405 (3.5) 64 (7.6) 6 (7.9) 
III-IV 92(0.8) 31 (3.7) 5 (6.6) 
Index hospitalization treatments    
Coronary angiography 10250 (88.2) 711 (83.9) 56 (73.7) 
PCI 6638 (57.1) 440 (51.9) 27 (35.5) 
Stenting  6292 (54.2) 399 (47.1) 26 (34.2) 
CABG 1209 (10.4) 73 (8.6) 7 (9.2) 
Clopidogrel 10633 (91.5) 790 (93.3) 68 (89.5) 

















  No MI 
(N=11,617) 
Type 1 MI 
(N=847) 
Type 2 MI 
(N=76) 
Glycoprotein IIb/IIIa inhibitors 2360 (20.3) 187 (22.1) 10 (13.2) 
Data presented as median (interquartile range) or n (%). 
Abbreviations: CABG, coronary artery bypass graft; CrCl, creatinine clearance; MI, myocardial 
infarction; PCI, percutaneous coronary intervention. 
†
 P-value <0.05 for assessing the univariate relationship between a baseline characteristic and type 1 MI 
controlling for randomized treatment. 
‡
 P-value <0.05 for assessing the univariate relationship between a baseline characteristic and type 2 MI 




















Table 2. Triggers of type 2 MIs 
Mechanisms N (%) 
Arrhythmias 29 (38.2)  
Atrial fibrillation/flutter 17  (22.4) 
Supraventricular tachycardia 9  (11.8) 
Ventricular tachycardia 3 (4.0) 
Anemia/bleeding 16 (21.1) 
Hypotension/shock 11 (14.5) 
Hypertension  9 (11.8) 
Sepsis/infection 8 (10.5)  
Heart failure 6 (7.9) 
Non-cardiac surgery 6 (7.9) 
Coronary spasm 3 (4.0) 
Stress 3 (4.0) 
Syncope 2 (2.6) 
Aortic stenosis 1 (1.3) 
Respiratory insufficiency 1 (1.3) 
More than one mechanism per type 2 myocardial infarction was identified in 16 patients. Information was 


















Table 3.  Cardiovascular death with type 1 MI and type 2 MI versus no MI 
  HR (95% CI) P value 
Based on first MI event   
Type 1 MI 8.90 (6.93–11.43) <.0001 
Type 2 MI  11.82 (5.71–24.46) <.0001 
Based on last MI event   
Type 1 MI 9.94 (7.74–12.76) <.0001 
Type 2 MI 19.15 (10.22–35.88) <.0001 
Excluding patients with multiple MI events   
Type 1 MI 7.59 (5.73–10.04) <.0001 
Type 2 MI 14.62 (7.04–30.34) <.0001 
Hazard ratios are adjusted for randomized treatment, age, sex, race, weight, region, smoking, 
hypertension, diabetes, hyperlipidemia, prior peripheral arterial disease, prior myocardial infarction, prior 
stroke, prior percutaneous coronary intervention, prior coronary artery bypass graft, features on 
presentation (ST-segment deviation, new T wave, Killip class, renal insufficiency), and treatments 
received during index stay (cardiac catheterization, percutaneous coronary intervention, coronary artery 
bypass graft, clopidogrel, aspirin, glycoprotein IIb/IIIa inhibitors).  































































 Provoking factors and clinical outcomes of patients with type 2 MIs are described. 
 
 Type 2 MIs were more prevalent in the first month after ACS. 
 
 Tachyarrhythmias and anemia or bleeding were the most common triggers of type 2 MIs. 
 
 Type 2 MI tended to be managed conservatively. 
 
 The hazard of cardiovascular death following type 2 MI was high.  
